On average, one in four adults has hypertension. 1 This figure is higher in certain regions of the world, and in certain areas within countries. Worldwide, however, the prevalence of hypertension is on the rise. The relationship between level of blood pressure and risk for cardiovascular events is linear and continuous.
All five major antihypertension classes of drugs, diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers (maybe not to be used as single first-line agents) are of benefit by reducing events, and do not differ significantly in their overall ability to reduce blood pressure in hypertension.
In numerous clinical trials, the control of blood pressure is achieved in only about half the time with monotherapy, even under strict trial conditions.
Concept of combination therapy
Combination therapy with two or more drugs will be necessary in the majority of hypertensive patients to achieve target blood pressure. Combination therapy will even be more frequently needed in diabetics and other high risk patients to reach the stricter goal blood pressure in these patients. Different classes of antihypertensive agents, when combined, often have greater antihypertensive effect than each on its own (synergistic effect) and may have better tolerability (two components minimising each other's side effects).
Despite this, the majority of trials of blood pressure lowering have focused on initial treatment with monotherapy.
Combination therapy: when to initiate?
Guidelines on hypertension, recommend that combination treatment be initiated as first-line therapy when there is a high cardiovascular risk: when the initial blood pressure is more than 20 mmHg systolic and 10 mmHg diastolic above the target (goal) blood pressure, when there is subclinical organ damage (diabetes, renal, cardiovascular disease). 2 The choice between initiating monotherapy or combination therapy is often based more on wisdom and experience than trial evidence. Combination therapy will also be initiated when monotherapy fails.
More than one line of evidence is emerging that an ARB plus a calcium channel blocker or diuretic provides effective blood pressure reduction, a high rate of blood pressure control with a better tolerability profile.
Calcium channel blockers with a diuretic or beta-blocker have been used in the FEVER, ELSA and VALUE trials, with great benefit.
The addition of an aldosterone antagonist (in low dose: 25 mg to 50 mg daily) to a drug regimen in resistant hypertension is often effective.
It is important to realise that there is no single optimal treatment for everyone with hypertension. When combinations of drugs are necessary to control blood pressure, physicians need to have choices.
Fixed dose (single pill) combinations
It was shown that a fixed combination pill, by reducing the number of pills to be taken, improves compliance significantly. 4 The availability of different fixed dose combinations of the same two drugs facilitates better titration. Fixed low-dose combinations are available (e.g. low-dose thiazide plus a low-dose "newer" beta-blocker) and are increasingly released on the market, which contributes to simplicity of administration and reduced side effects. However, much more data are needed on fixed-dose combinations as preferred agents.
Which combination is potentially unwise?
It is prudent not to use a nondihydropyridine plus a betablocker, due to excessive heart rate reduction.
The older type of beta-blocker/diuretic combination in high doses favours the development of diabetes and should be avoided (especially in the young and obese individuals).
The combination of an ACE-inhibitor with an ARB has no proven benefit and could lead to more side effects.
Conclusion
New and old evidence strongly supports combination treatment as the most effective way to control blood pressure.
There are a number of likely combinations of drug therapy for hypertension from which the physician can choose. Currently, renin-angiotensin system blockade combined with a calcium channel blocker or a diuretic are commonly used. Designed to explore how the benefits of active treatment of isolated systolic hypertension were distributed across patient groups according to gender and previous cardiovascular complications, and whether the morbidity and mortality results were influenced by age, level of systolic or diastolic blood pressure, smoking or drinking habits, or diabetes mellitus. Patients 60 years or older (systolic BP 160-219 mm Hg, diastolic BP < 95 mm Hg were enrolled. 1 253 patients were assigned to active treatment (initial nitrendipine, 10-40 mg, with possible captopril, 12.5-50 mg, and/or hydrochlorothiazide, 12.5-50 mg). 1 141 control patients received placebo.
In elderly Chinese patients with isolated systolic hypertension, stepwise antihypertensive drug treatment improved prognosis. The benefit was particularly evident in diabetic patients and, for cardiac end points, non-smokers. There is often a higher incidence of cardiovascular complications in hypertensive patients on treatment than in normotensive individuals, possibly as a result of inadequate reduction of blood pressure. The investigators aimed to assess the optimum target diastolic blood pressure, and the potential benefit of a low dose of aspirin in the treatment of hypertension. 18 790 patients, aged 50-80 years with hypertension and diastolic blood pressure of 100-115 mmHg (mean 105 mmHg) were randomly assigned a target diastolic blood pressure. 6264 patients were allocated the target of < 90 mmHg, 6 264 < 85 mmHg, and 6 262 < 80 mmHg. Felodipine was given as baseline therapy with the addition of other agents, according to a five-step regimen. In addition, 9 399 patients were randomly assigned 75 mg/day aspirin and 9 391 patients were assigned placebo.
HOT
Intensive lowering of blood pressure was associated with a low rate of cardiovascular events, with benefits when the diastolic blood pressure was lowered 82.6 mmHg. Aspirin significantly reduced major cardiovascular events, particularly myocardial infarction. There was no effect on the incidence of stroke or fatal bleeds, but non-fatal major bleeds were twice as common. The investigators hypothesised that treatment with an ACE inhibitor combined with a dihydropyridine calcium channel blocker would reduce the rate of cardiovascular events more effectively than treatment with an ACE inhibitor plus a thiazide diuretic. 11 506 hypertensive patients at high risk for cardiovascular events were randomised to receive benazepril plus amlodipine, or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for angina, resuscitation after sudden cardiac arrest, and coronary revascularisation.
INVEST
Benazepril-amlodipine was superior to benazepril-hydrochlorothiazide in reducing cardiovascular events in patients who were at high risk for such events. This study was designed to determine the effects of a blood pressure-lowering regimen in hypertensive and non-hypertensive patients with a history of stroke or transient ischaemic attack. 6 105 individuals were randomly assigned active treatment (3 051) or placebo (3 054). Active treatment consisted of a regimen based on perindopril (4 mg), with the addition of the diuretic indapamide at the discretion of treating physicians. The primary outcome was total stroke (fatal or non-fatal).
PROGRESS
The regimen reduced the risk of stroke among both hypertensive and nonhypertensive individuals with a history of stroke or transient ischaemic attack. Combination therapy with perindopril and indapamide produced larger blood pressure and risk reductions. This trial assessed the effects of the routine administration of an ACE inhibitor-diuretic combination on serious vascular events in patients with diabetes, irrespective of initial blood pressure levels or the use of other antihypertensives. 11 140 patients with type 2 diabetes received either a combination of perindopril and indapamide or placebo, in addition to current therapy. The primary end points were composites of major macrovascular and microvascular events, defined as death from cardiovascular disease, non-fatal stroke or non-fatal myocardial infarction, and new or worsening renal or diabetic eye disease.
ADVANCE
Routine administration of perindopril and indapamide to patients with type 2 diabetes was well tolerated and reduced the risks of major vascular events, including death.
HYVET Hypertension in the Very Elderly Trial
Beckett NS, Peters R, Fletcher AE; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
It was unclear whether there is any benefit in the treatment of patients with hypertension who are 80 years or older; antihypertensive therapy may reduce the risk of stroke, but could possibly increase the risk of death. 3 845 hypertensive patients, 80 years or older, were randomised to receive either indapamide (sustained release, 1.5 mg) or placebo. Perindopril (2 or 4 mg), or placebo, was added if necessary to achieve the target blood pressure of 150/80 mmHg. The primary end point was fatal or non-fatal stroke.
Antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older, is beneficial. Left ventricular hypertrophy is a good indicator of risk of cardiovascular morbidity and death.
LIFE
The investigators wanted to establish whether selective blocking of angiotensin II improves hypertrophy beyond reducing blood pressure, and if this reduces cardiovascular morbidity and death. 9 193 hypertensive participants, with left ventricular hypertrophy were assigned losartan-based or atenolol-based treatment for at least four years, until 1 040 patients had a primary cardiovascular event (death, myocardial infarction, stroke).
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure, is better tolerated, and seems to confer benefits beyond reduction in blood pressure. The objective was to assess whether candesartan-based antihypertensive treatment in elderly patients, with mild to moderate hypertension, causes a reduction in cardiovascular events, cognitive decline and dementia. 4 964 patients, aged 70-89 years, were assigned randomly to receive candesartan or placebo, with open-label antihypertensive therapy added on if needed. The primary outcome measure was a composite of cardiovascular death, nonfatal stroke and non-fatal myocardial infarction, and secondary outcome measures included cardiovascular death, stroke and myocardial infarction, cognitive function and dementia.
SCOPE
A slightly more effective blood pressure reduction with candesartanbased therapy was associated with a statistically non-significant reduction in major cardiovascular events and with a marked reduction in non-fatal stroke.
Cognitive function was well maintained in both treatment groups. Both treatment regimens were generally well tolerated. The study was designed to compare the incidence of stroke and other cardiovascular events in patients receiving a low-dose diuretic and a low-dose calcium antagonist combination, with those on low-dose diuretic monotherapy, and assess the effects of a small blood pressure difference at levels lower than those achieved in previous trials. 9 800 Chinese hypertension patients, with additional cardiovascular risk factors/disease, were enrolled. Six weeks after switching to low-dose (12.5 mg) hydrochlorothiazide, if their blood pressure was in the range 140-180 mmHg (systolic) or 90-100 mmHg (diastolic), they were assigned to lowdose felodipine extended release or placebo, and followed up for 40 months.
In these moderately complicated patients, a difference in SBP/DBP as small as 4/2 mmHg is associated with substantial reductions in the incidence of most cardiovascular events. Usually, the cardiovascular complications of hypertension arise as a result of atherosclerosis. Some antihypertensive agents influence atherosclerosis independently of blood pressure lowering. This trial in 2 334 patients with hypertension compared the effects of four-year treatment with either lacidipine or atenolol on an index of carotid atherosclerosis, the mean of the maximum intima media thicknesses. This index has been shown by epidemiological studies to be predictive of cardiovascular events.
ELSA
The greater efficacy of lacidipine on carotid intima media thickness progression and number of plaques per patient, despite a smaller ambulatory blood pressure reduction, indicates an antiatherosclerotic action independent of antihypertensive action. The trial was designed to test the hypothesis that, for the same blood pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. 15 245 patients, 50 years and older, with hypertension and high risk of cardiac events participated in a comparison of therapy based on valsartan or amlodipine. The trial lasted until at least 1 450 patients had reached a primary endpoint, a composite of cardiac mortality and morbidity. Patients were followed up for 4.2 years.
VALUE
The main outcome of cardiac disease did not differ between the treatment groups. Unequal reductions in blood pressure might account for differences between the groups.
